SGHT — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• Revenue was $23.4 million during the three months ended June 30, 2026, an increase of $3.8 million, or 19.6% compared to $19.6 million in the prior year comparable period. For the six months ended June 30, 2026, revenue was $43.1 million, an increase of $6.0 million, or 16.2% compared to $37.1 milli…

• Interventional Glaucoma segment revenue for the three months ended June 30, 2026 increased by $1.5 million, or 7.7%, to $20.7 million, compared to $19.2 million for the three months ended June 30, 2025. Interventional Glaucoma revenue for the six months ended June 30, 2026 increased by $2.7 million,…

• Interventional Dry Eye segment revenue for the three months ended June 30, 2026 increased by $2.3 million, or 703.3%, to $2.7 million, compared to $0.3 million for the three months ended June 30, 2025. Interventional Dry Eye revenue for the six months ended June 30, 2026 increased by $3.3 million, o…

• Cost of goods sold was $2.0 million during the three months ended June 30, 2026, a decrease of $1.0 million, or 32.3%, from $3.0 million in the prior year comparable period. Cost of goods sold for the six months ended June 30, 2026, was $4.7 million, a decrease of $0.7 million or 12.2% from $5.4 mil…

• Interventional Glaucoma segment cost of goods sold decreased $1.2 million and $1.1 million in the three and six months ended June 30, 2026, respectively, compared to the prior year comparable periods, primarily due to $1.2 million of tariff refunds received in the second quarter of 2026. For the six…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• Revenue was $19.7 million during the three months ended March 31, 2026, an increase of $2.2 million, or 12.5% compared to $17.5 million in the prior year comparable period, primarily as a result of the following:

• Interventional Glaucoma segment revenue for the three months ended March 31, 2026 was $18.3 million, an increase of $1.2 million, or 7.2%, from the prior year comparable period. The overall increase in Interventional Glaucoma revenue was primarily attributable to an increase in the number of OMNI un…

• Interventional Dry Eye segment revenue for the three months ended March 31, 2026 was $1.4 million, an increase of $1.0 million, or 244%, from the prior year comparable period. The overall increase in Interventional Dry Eye revenue was primarily due to increased average selling prices and an increase…

• Cost of goods sold was $2.7 million during the three months ended March 31, 2026, an increase of $0.3 million, or 12.7%, from $2.4 million in the prior year comparable period, primarily as a result of the following:

• Interventional Glaucoma segment cost of goods sold was relatively flat compared to the prior year comparable period despite increased unit sales.

Text added vs the prior filing · source: 10-Q · 2026-08-05

• There have been no material changes to our primary risk exposures from those described under the heading "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• the fair value of these assets as a result of changes in interest rates due to the short-term nature of our cash and cash equivalents.

• The Hercules Loan Agreement contains a floating rate equal to the greater of 10.35% or the Prime Rate plus 2.35%, with an interest rate equal to 10.35% as of March 31, 2026. Based upon the balance outstanding as of March 31, 2026, a hypothetical 1.0% (100 basis points) change in interest rates would…

• There have been no material changes to such risks from those described in our Annual Report under the heading "Quantitative and Qualitative Disclosures About Market Risk."

Text added vs the prior filing · source: 10-Q · 2026-08-05

• In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily is required…

• Under the supervision and with the participation of management, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2026. Based on that evaluation, our principal executive officer and principal financial and accounting …

• There were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act, during the three months ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• Based on this evaluation, our principal executive officer and principal financial and accounting officer concluded that as of March 31, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.

• There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial report…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• From time to time, we are involved in various legal proceedings, regulatory matters, and other disputes or claims arising from or related to claims incident to the normal course of our business activities, including actions with respect to intellectual property, employment, regulatory and product li…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• Except as set forth in Note 6, Commitments and Contingencies, to the notes to the unaudited condensed consolidated financial statements in Part I, Item 1, “Financial Information” of this Quarterly Report, which is incorporated herein by reference, we do not believe we are currently a party to any le…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• An investment in our common stock involves risks. Before making an investment decision, you should carefully consider all the information under the heading, "Management’s Discussion and Analysis of Financial Condition and Results of Operations," as well as in our unaudited condensed consolidated fin…

• We are not aware of any material changes to the risks and uncertainties described under the heading "Risk Factors" in our Annual Report, which information is incorporated herein by reference.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• We are not aware of any material changes to the risks and uncertainties described under the heading “Risk Factors” in our Annual Report, which information is incorporated herein by reference. The risks described in our Annual Report are not the only ones we face. Additional risks we currently do not…

• believe to be immaterial may also impair our business, financial condition, operating results, liquidity, and future prospects.